

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant:	SALONEN et al.	Conf.:	UNASSIGNED
Appl. No.:	NEW	Group:	UNASSIGNED
Filed:	October 24, 2003	Examiner:	UNASSIGNED
For:	A DNA MOLECULE ENCODING A VARIANT PARAOXONASE AND USES THEREOF		

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

October 24, 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).
09/811,673

U.S. Filing Date(s)
March 20, 2001

III. FEES


This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Mark J. Nuell, #36,623

DRN/enm
0933-0216P

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000

Attachment(s) : ☒ PTO-1449(s)

☐ References

☐ Foreign Search Report

☐ Other:

(Rev. 09/30/03)

Form PTO-1449				ATTY DOCKET NO. 0933-0167P		APPLICATION NO. NEW	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				APPLICANT SALONEN et al.			
				FILING DATE October 24, 2003		GROUP UNASSIGNED	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS TRANSLATION YES NO
		WO0128365	A1	2001-04-26	PCT		
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.							
	SALONEN et al., Supplement II Circulation, Vol. 104, No. 17, pp. 3794, (2001).						
	LA DU et al., Chem. Biol. Interactions, vol. 87, pp. 25-34, (1993).						
	CLENENNING et al., Genomics, Vol. 35, pp. 586-589, (1996).						
	PRIMO-PARMO et al., Genomics, Vol. 33, pp. 498-507, (1996).						
	LEVIEV et al., Arterioscler Thromb. Vasc. Biol., Vol. 20, pp. 516-521, (2000).						
	BROPHY et al., Pharmacogenetics, Vol. 11, pp. 77-84, (2001).						
	WOOD et al., J. Steroid Biochem. Molec. Biol., Vol. 59, pp. 472-473, (1996).						
	ZABETIAN et al., Am. J. Hum. Genet., Vol. 68, pp. 515-522, (2001).						
	MASATO et al., Jap. J. of Electrophoresis, Vol. 38, No. 3, pp. 81-88, (1994).						
	KOLOSHA et al., Human Mutation, Vol. 15, pp. 447-453, (2000).						
	YAMADA et al., Biochemical and Biophysical Res. Comm., Vol. 236, No. RC977047, pp. 772-775, (1997).						
	MAEKAWA et al., Clinical Chemistry, Vol. 43, No. 6, pp. 924-929, (1997).						
	LANDEGREN et al., Genome Research, Vol. 8, pp. 769-776, (1998).						
EXAMINER				DATE CONSIDERED			
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

Form PTO-1449				ATTY DOCKET NO. 0933-0167P		APPLICATION NO. NEW	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				APPLICANT SALONEN et al.			
				FILING DATE October 24, 2003		GROUP UNASSIGNED	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
FOREIGN PATENT DOCUMENTS							
	Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS
						TRANSLATION	
						YES	NO
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)							
	J. T. Salonen et al., <i>Diabetes</i> , Vol. 47, pp. 270-275 (Feb. 1998)						
	S. A. Everson et al., <i>Psychosomatic Medicine</i> , 58: 113-121 (1996)						
	L. Teppo et al., <i>Acta Oncologica</i> , Vol. 33, No. 4, pp. 365-369 (1994)						
	M. Ihanainen et al., <i>Nutrition Research</i> , Vol. 9, pp. 597-604 (1989)						
	J. T. Salonen et al., <i>BMJ</i> , Vol. 311, pp. 1124-1127 (Oct. 1995)						
	T. A. Lakka et al., <i>New England Journal of Medicine</i> , 330:1549-1554 (June 1994)						
	J. T. Salonen et al., <i>Circulation</i> , Vol. 86, No. 3, pp. 803-811 (Sept. 1992)						
	J. T. Salonen et al., <i>Annals of Clinical Research</i> , 20: 46-50 (1988)						
	M. I. Mackness et al., <i>The Lancet</i> , Vol. 349, pp. 851-852 (March 1997)						
	M. I. Mackness et al., <i>Biochem. J.</i> , 245: 293-296 (1987)						
	M. I. Mackness et al., <i>FEBS</i> , Vol. 286, No. 1, 2, pp. 152-154 (July 1991)						
	B. N. La Du et al., <i>Chem.-Biol. Interactions</i> , 87 (1993) 25-34						
	R. Humbert et al., <i>Nature Genetics</i> , Vol. 3, pp. 73-76 (Jan. 1993)						
	H. G. Davies et al., <i>Nature Genetics</i> , Vol. 14, pp. 334-336 (Nov. 1996)						
EXAMINER				DATE CONSIDERED			
<small>EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>							

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

ATTY DOCKET NO.
0933-0167PAPPLICATION NO.
NEWAPPLICANT
SALONEN et al.FILING DATE
October 24, 2003GROUP
UNASSIGNED

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
---------------------	-----------------	------	------	------	-------	--------------	-------------------------------

FOREIGN PATENT DOCUMENTS

Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO

OTHER DOCUMENTS

(Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.

D. M. Shih et al., *Nature*, Vol. 394, pp. 284-287 (July 1998)M. C. Blatter Garin et al., *J. Clin. Invest.*, Vol. 99, No. 1, pp. 62-66 (Jan. 1997)B. Mackness et al., *British J. of Pharm.*, Vol. 122:265-268 (1997)M. I. Mackness et al., *Atherosclerosis*, 86: 193-199 (1991)B. Mackness et al., *The Lancet*, Vol. 353, No. 9151 (Feb. 1999)M. I. Mackness et al., *Current Opinion in Lipidology*, 7:69-76 (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.